Cardiol Therapeutics Files 6-K Report
Ticker: CRDL · Form: 6-K · Filed: Jun 25, 2024 · CIK: 1702123
Sentiment: neutral
Topics: regulatory-filing, news-release
TL;DR
Cardiol Therapeutics filed a 6-K, check the exhibits for news.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on June 25, 2024, reporting a news release dated June 2024. The company, based in Oakville, Ontario, Canada, is involved in the biological products sector.
Why It Matters
This filing indicates ongoing corporate activity and reporting for Cardiol Therapeutics Inc., which is relevant for investors tracking the company's regulatory compliance and disclosures.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign private issuers and typically contains limited new material information beyond what is disclosed in accompanying press releases.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- Oakville, Ontario, Canada (location) — Principal executive offices
- June 25, 2024 (date) — Filing date
- June 2024 (date) — Reporting period
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer submitted pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of June 2024, and it includes a news release as an exhibit.
Where is Cardiol Therapeutics Inc. located?
Cardiol Therapeutics Inc.'s principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
What is the Commission File Number for Cardiol Therapeutics Inc.?
The Commission File Number for Cardiol Therapeutics Inc. is 001-40712.
What type of company is Cardiol Therapeutics Inc. classified as by SIC code?
Cardiol Therapeutics Inc. is classified under Standard Industrial Classification code 2836, which is for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is included as an exhibit with this Form 6-K?
Exhibit 99.1 is included, which is a News Release dated June 2024.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-06-25 07:28:27
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 7KB
- exhibit99-1xu001.jpg (GRAPHIC) — 7KB
- 0001062993-24-013002.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: June 25, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer